LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
Hlb Co. Ltd.
Headquarters:
Ulsan, South Korea
Website:
http://www.hlbkorea.com/
Year Founded:
1985
Status:
Public
Industry Sector:
HealthTechnology
CEO:
Yang-Gon Jin
Number Of Employees:
168
Enterprise Value:
$6,546,736,567
PE Ratio:
-82.11
Exchange/Ticker 1:
KOSDAQ:028300
Exchange/Ticker 2:
N/A
Latest Market Cap:
$5,411,231,201
BioCentury
|
Apr 4, 2025
Data Byte
First PDUFA date missed on RFK Jr.’s watch
FDA has at least seven more target action dates coming up in April
Read More
BioCentury
|
Mar 14, 2025
Data Byte
Ten PDUFA dates on FDA’s March agenda
Upcoming decisions include a label expansion for Alnylam’s Amvuttra, a new siRNA therapy for hemophilia, and more
Read More
BioCentury
|
Dec 10, 2024
Deals
Frustrated by IRA, Relay out-licenses ‘NDA-ready’ program to Elevar
Also in BioCentury’s Deals Report, a trio of biotech deals by GSK, and more
Read More
BioCentury
|
Jul 9, 2024
Finance
2Q24 Wrap: Trickle down recovery?
Biopharmas above $5B in market cap are up, but everyone else languishes
Read More
BioCentury
|
Apr 5, 2024
Finance
1Q24 wrap: Red rising
Winners, losers in biotech stock tiers in 1Q24
Read More
BioCentury
|
Oct 28, 2021
Management Tracks
Labinger out as Checkmate CEO
Plus: Travecta, MTS Health Partners, Elevar and Y Combinator
Read More
BioCentury
|
Apr 28, 2020
Finance
April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic
Read More
Items per page:
10
1 - 7 of 7
Help Center
Username
Request Training
Submit Data Correction
Ask a Question
Elevio by Dixa
Help